Viking Therapeutics Inc
VKTXHealthcare|Biotechnology|USA
$38.86
-2.28 (-5.54%)
Tangible Book
$4.33
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07104383 VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Weight Loss | P3 | Active | 1,100 | RCT, Double-blind | VK2735 |
| NCT07104500 VK2735 for Weight Management Phase 3 | Weight Loss | P3 | Active | 4,500 | RCT, Double-blind | VK2735 |
| NCT06068946 VK2735 for Weight Management Phase 2 | Weight Loss | P2 | Completed | 176 | RCT, Double-blind | VK2735, Placebo |
| NCT06828055 VK2735 for Weight Management Phase 2 (Venture Oral Dosing) | Weight Loss | P2 | Completed | 280 | RCT, Double-blind | Placebo, VK2735 |
| NCT02927184 Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease | Hyperlipidemia, NAFLD | P2 | Completed | 59 | RCT, Double-blind | VK2809, Placebo |
| NCT02578095 Acute Hip Fracture Study in Patients 65 Years or Greater | Hip Fractures | P2 | Completed | 108 | RCT, Double-blind | VK5211, Placebo |
| NCT04173065 A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH | NASH - Nonalcoholic Steatohepatitis | P2 | Completed | 248 | RCT, Double-blind | VK2809, Placebos |
| NCT04973657 A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN | Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) | P1 | Completed | 24 | RCT, Double-blind | VK0214 |
| NCT05203237 Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 | Weight Loss, NASH | P1 | Completed | 92 | RCT, Double-blind | VK2735, Placebo, VK2735 Placebo, VK2735 Drug |